Lhasa Limited shared knowledge shared progress

Adverse outcome pathways Publications

The following links provide access to relevant Adverse outcome pathways publications for the last 2 years. If you would like to view older publications, or to refine your search criteria further please search the library.

TitlePublishedTypeProducts
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk - SOT 2021 Presentation SlidesMarch 2021pdf fileDerek Nexus
Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and postmarketing reportsMarch 2021
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk - PETA Science Consortium Webinar SlidesMarch 2021pdf file
Bringing Together Scientific Disciplines for Collaborative Undertakings: A Vision for Advancing the Adverse Outcome Pathway FrameworkFebruary 2021pdf file
Beyond adverse outcome pathways: making toxicity predictions from event networks, SAR models, data and knowledgeJanuary 2021
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic RiskDecember 2020pdf file
Application of adverse outcome pathways (AOPs) to support genotoxicity assessmentNovember 2020pdf file
Session 4 - The growing network of genotoxicity AOPs - RecordingOctober 2020
Session 4 - The growing network of genotoxicityAOPs - SlidesOctober 2020pdf file
Session 4 - Combining knowledge and data on an AOP framework in order to take advantage of new and emerging methods In genotoxicity assessment - SlidesOctober 2020pdf file
Session 4 - Combining knowledge and data on an AOP framework in order to take advantage of new and emerging methods In genotoxicity assessment - RecordingOctober 2020
Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - SlidesOctober 2020pdf file
Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - RecordingOctober 2020
Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - SlidesOctober 2020pdf file
Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - RecordingOctober 2020
Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - SlidesOctober 2020pdf file
Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - RecordingOctober 2020
Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - SlidesOctober 2020pdf file
Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - RecordingOctober 2020
Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - RecordingOctober 2020
Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - SlidesOctober 2020pdf file
Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - SlidesOctober 2020pdf file
Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - RecordingOctober 2020
Linking Evidence With AOPs To Produce Integrated Approaches to Testing and Assessment (IATA)September 2020pdf file
Integrating Knowledge Of Carcinogenicity Adverse Outcome Pathways (AOPs) With Experimental Data_EMGS Data Challenge 2020September 2020pdf fileDerek NexusVitic Nexus
Evaluation of the Global Performance of Eight In Silico Skin Sensitization Models Using Human DataMay 2020Derek Nexus
The Application of Adverse Outcome Pathways (AOPs) for Risk AssessmentMay 2020pdf file
Utilising Adverse Outcome Pathways as a Framework to Organise Evidence and Support Carcinogenicity Risk AssessmentMarch 2020pdf file
Predicting the safety of medicines in pregnancy: A workshop reportMarch 2020
Future Developments AOP Networks And Predicting Secondary PharmacologyJanuary 2020pdf file
Carcinogenicity Adverse Outcome PathwaysJanuary 2020pdf fileDerek NexusVitic Nexus
Using an Adverse Outcome Pathway framework to ground approaches in predictive toxicologyNovember 2019pdf file

© 2021 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.